D. Western Therapeutics Institute, Inc. (FRA:6DW)

FRA:6DW Cash Flow Statement

Financials in millions JPY. Fiscal year is January - December.

Fiscal Year	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Net Income	-1,288	-826	-440	-159	-289
Depreciation & Amortization	49	48	46	45	44
Loss (Gain) From Sale of Assets	-	6	-	-	-
Loss (Gain) From Sale of Investments	-	12	100	-	-
Other Operating Activities	-3	2	1	-3	-
Change in Accounts Receivable	-7	53	-113	-9	11
Change in Inventory	-14	22	9	-30	1
Change in Accounts Payable	-74	95	22	4	12
Change in Other Net Operating Assets	38	2	21	-24	5
Operating Cash Flow	-1,299	-586	-354	-176	-216
Capital Expenditures	-9	-12	-9	-2	-5
Sale (Purchase) of Intangibles	-1	-2	-	-	-
Investment in Securities	-	-	-130	-109	-7
Other Investing Activities	-	-1	-	-	-1
Investing Cash Flow	-10	-15	-139	-111	-13
Long-Term Debt Issued	886	166	913	-	100
Long-Term Debt Repaid	-1,034	-120	-120	-120	-120
Net Debt Issued (Repaid)	-148	46	793	-120	-20
Issuance of Common Stock	715	88	87	15	1,024
Other Financing Activities	-	-	-13	1	-
Financing Cash Flow	567	134	867	-104	1,004
Foreign Exchange Rate Adjustments	-	-	28	17	-6
Miscellaneous Cash Flow Adjustments	1	-	-2	-	-2
Net Cash Flow	-741	-467	400	-374	767
Free Cash Flow	-1,308	-598	-363	-178	-221
Free Cash Flow Margin	-277.71%	-139.72%	-81.03%	-42.99%	-62.25%
Free Cash Flow Per Share	-37.24	-18.82	-12.25	-6.07	-8.13
Cash Interest Paid	5	2	2	4	4
Cash Income Tax Paid	1	1	1	1	1
Levered Free Cash Flow	-871.38	-317	-225.13	-126	-129.75
Unlevered Free Cash Flow	-868.25	-315.75	-223.25	-123.5	-127.25
Change in Working Capital	-57	172	-61	-59	29

Source: S&P Global Market Intelligence. Standard template. Financial Sources.